Rhenium-188 Production in Hospitals, by W-188/re-188 Generator, for Easy Use in Radionuclide Therapy

Overview

Journal Int J Mol Imaging

Date 2013 May 9

PMID 23653859

Citations 13

Authors

Maria Argyrou

Alexia Valassi

Maria Andreou

Maria Lyra

Affiliations

Soon will be listed here.

Abstract

Rhenium-188 (Re-188) is a high energy β-emitting radioisotope obtained from the tungsten-188/rhenium-188 (W-188/Re-188) generator, which has shown utility for a variety of therapeutic applications in nuclear medicine, oncology, and interventional radiology/cardiology. Re-188 decay is accompanied by a 155 keV predominant energy γ-emission, which could be detected by γ-cameras, for imaging, biodistribution, or absorbed radiation dose studies. Its attractive physical properties and its potential low cost associated with a long-lived parent make it an interesting option for clinical use. The setup and daily use of W-188/Re-188 generator in hospital nuclear medicine departments are discussed in detail. The clinical efficacy, for several therapeutic applications, of a variety of Re-188-labeled agents is demonstrated. The high energy of the β-emission of Re-188 is particularly well suited for effective penetration in solid tumours. Its total radiation dose delivered to tissues is comparable to other radionuclides used in therapy. Furthermore, radiation safety and shielding requirements are an important subject of matter. In the case of bone metastases treatment, therapeutic ratios are presented in order to describe the efficacy of Re-188 usage.

Citing Articles

Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.

Sharma S, Pandey M Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895931 PMC: 10610335. DOI: 10.3390/ph16101460.

NGR-Based Radiopharmaceuticals for Angiogenesis Imaging: A Preclinical Review.

Trencsenyi G, Enyedi K, Mezo G, Halmos G, Kepes Z Int J Mol Sci. 2023; 24(16).

PMID: 37628856 PMC: 10454655. DOI: 10.3390/ijms241612675.

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.

Holik H, Ibrahim F, Elaine A, Putra B, Achmad A, Kartamihardja A Molecules. 2022; 27(10).

PMID: 35630536 PMC: 9143622. DOI: 10.3390/molecules27103062.

Bifunctional chelators for radiorhenium: past, present and future outlook.

Melis D, Burgoyne A, Ooms M, Gasser G RSC Med Chem. 2022; 13(3):217-245.

PMID: 35434629 PMC: 8942221. DOI: 10.1039/d1md00364j.

Involvement of Differentially Expressed microRNAs in the PEGylated Liposome Encapsulated Rhenium-Mediated Suppression of Orthotopic Hypopharyngeal Tumor.

Lin B, Wan S, Lin M, Chang C, Chen T, Yang M Molecules. 2020; 25(16).

PMID: 32784458 PMC: 7463599. DOI: 10.3390/molecules25163609.

References

Dadachova E, Bouzahzah B, Zuckier L, Pestell R . Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol. 2002; 29(1):13-8. DOI: 10.1016/s0969-8051(01)00279-7. View

Blower P, Lam A, ODoherty M, Kettle A, Coakley A, Knapp Jr F . Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies. Eur J Nucl Med. 1998; 25(6):613-21. DOI: 10.1007/s002590050263. View

Bolch W, Bouchet L, ROBERTSON J, Wessels B, Siegel J, Howell R . MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med. 1999; 40(1):11S-36S. View

Garin E, Denizot B, Noiret N, Lepareur N, Roux J, Moreau M . 188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma. Nucl Med Commun. 2004; 25(10):1007-13. DOI: 10.1097/00006231-200410000-00004. View

Stabin M . MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996; 37(3):538-46. View

Lepareur N, Ardisson V, Noiret N, Garin E . (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside. Int J Mol Imaging. 2012; 2012:278306. PMC: 3299367. DOI: 10.1155/2012/278306. View

Maxon 3rd H, Schroder L, Washburn L, Thomas S, Samaratunga R, Biniakiewicz D . Rhenium-188(Sn)HEDP for treatment of osseous metastases. J Nucl Med. 1998; 39(4):659-63. View

Garin E, Noiret N, Malbert C, Lepareur N, Roucoux A, Caulet-Maugendre S . Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs. Eur J Nucl Med Mol Imaging. 2003; 31(4):542-6. DOI: 10.1007/s00259-003-1402-z. View

Boschi A, Uccelli L, Duatti A, Colamussi P, Cittanti C, Filice A . A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nucl Med Commun. 2004; 25(7):691-9. DOI: 10.1097/01.mnm.0000130241.22068.45. View

10.

Jeong J, Knapp Jr F . Use of the Oak Ridge National Laboratory tungsten-188/rhenium-188 generator for preparation of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy. Semin Nucl Med. 2008; 38(2):S19-29. DOI: 10.1053/j.semnuclmed.2007.10.003. View

11.

Torres-Garcia E, Ferro-Flores G, Arteaga de Murphy C, Correa-Gonzalez L, Pichardo-Romero P . Biokinetics and dosimetry of 188Re-anti-CD20 in patients with non-Hodgkin's lymphoma: preliminary experience. Arch Med Res. 2007; 39(1):100-9. DOI: 10.1016/j.arcmed.2007.06.023. View

12.

Lambert B, de Klerk J . Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy. Nucl Med Commun. 2006; 27(3):223-9. DOI: 10.1097/00006231-200603000-00004. View

13.

Lambert B, Bacher K, Defreyne L . Rhenium-188 based radiopharmaceuticals for treatment of liver tumours. Q J Nucl Med Mol Imaging. 2009; 53(3):305-10. View

14.

Liepe K, Kropp J, Runge R, Kotzerke J . Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer. 2003; 89(4):625-9. PMC: 2376909. DOI: 10.1038/sj.bjc.6601158. View

15.

Savio E, Gaudiano J, Robles A, Balter H, Paolino A, Lopez A . Re-HEDP : pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose. BMC Nucl Med. 2001; 1(1):2. PMC: 60657. DOI: 10.1186/1471-2385-1-2. View

16.

Stabin M, Sparks R, Crowe E . OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005; 46(6):1023-7. View

17.

Biersack H, Palmedo H, Andris A, Rogenhofer S, Knapp F, Guhlke S . Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med. 2011; 52(11):1721-6. DOI: 10.2967/jnumed.111.093674. View

18.

Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf I, Reinhardt M, Ezziddin S . Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol. 2003; 21(15):2869-75. DOI: 10.1200/JCO.2003.12.060. View

19.

Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A . EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2008; 35(10):1934-40. DOI: 10.1007/s00259-008-0841-y. View

20.

Lambert B, Bacher K, Defreyne L, Gemmel F, Van Vlierberghe H, Jeong J . 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med. 2005; 46(1):60-6. View